Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)

NCT06784791 is registered in ClinicalTrials.gov with University Hospital, Essen as lead sponsor.

NCT NCT06784791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06784791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)
Lead sponsor
University Hospital, Essen
Phase
Phase 2
Overall status
Recruiting
Start date
November 6, 2024
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer (nsclc)